SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
BUENA, N.J., March 05, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James 39th Annual Institutional Investors Conference. The Conference is taking place March 4-7, 2018 at the J.W. Marriott Grande Lakes, Orlando, FL.
Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Wednesday March 7th at 9:15 a.m. ET.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Martin Wilson
Teligent, Inc.
856-336-9120
www.teligent.com
